Navigation Links
Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/2/2013

LAVAL, Quebec, May 2, 2013 /PRNewswire/ --

  •  2013 First Quarter Total Revenue $1.068 billion; an increase of 25% over the prior year
  •  2013 First Quarter Product Sales $1.039 billion; an increase of 38% over the prior year
  •  Organic growth (same store sales) was 6%, excluding the impact from generics, primarily BenzaClin and Cesamet
  •  Pro forma organic growth was 4%, excluding the impact from generics, primarily BenzaClin and Cesamet
  •  2013 First Quarter GAAP EPS Loss of $0.09; Cash EPS $1.30, an increase of 43% over the prior year, excluding one-time items in 2012 first quarter
  •  2013 First Quarter GAAP Operating Cash Flow $255 million; Adjusted Operating Cash Flow $345 million; an increase of 35% over the prior year, excluding one-time items in 2012 first quarter
  •  2013 Guidance for Cash EPS raised to $5.55 to $5.85 despite entry of Zovirax generic ointment
  • Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces first quarter financial results for 2013.

    "Despite a slow January due to the integration of the Valeant and Medicis sales organizations, we delivered another solid quarter of strong growth in Cash EPS and adjusted cash flow to our shareholders," stated J. Michael Pearson, chairman and chief executive officer.  "We were particularly pleased with the strong organic growth of our emerging market segment, which was primarily driven by Poland, Russia, Brazil, South East Asia, and South Africa, as well as the continued growth in many of our promoted brands."

    RevenueValeant's total revenues were $1.068 billion, up 25% compared to the first quarter of 2012, and product revenues were $1.039 billion, up 38% versus the year-ago quarter. 

    Valeant's U.S. Promoted product sales increased 91% to $479 million led by strong growth in
    '/>"/>

    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
    2. Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
    3. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
    4. Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
    5. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
    6. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
    7. Valeant Pharmaceuticals Provides Update to Recent Event
    8. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
    9. Valeant Pharmaceuticals Announces Private Exchange Offer
    10. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
    11. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Research and Markets has announced the addition ... Pipeline Insight 2014" report to their offering. ... eradicate the prevalence of cancer have achieved limited success ... specificity, safety and large number of side effects, which ... It has been discovered that peptides can be used ...
    (Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
    (Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present ... Australian and New Zealand Forensic Science Society,s 22 ... in Adelaide, Australia .  Forensic ... the advancements that hyperspectral imaging can bring to ... Beckstead , Director of Product Development at ChemImage, ...
    Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
    ... 16 Reportlinker.com announces that a ... in its catalogue. , ... Market Outlook To 2014: Policy environment, ... , http://www.reportlinker.com/p0155347/Reportlinker-Adds-The-Middle-Eastern-Pharmaceutical-Market-Outlook-To-2014-Policy-environment-market-structure-competitive-landscape-growth-opportunities.html ...
    ... Oct. 16 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... meeting at 1:30 p.m. eastern time on Oct. 19, 2009. ... the management presentation which will follow. During that presentation, management ... , The webcast can be accessed via a link on ...
    Cached Medicine Technology:Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 11
    (Date:8/31/2014)... An analysis of 32 studies compiled by ... link between lower levels of Vitamin D and a ... August 2014 issue of American Journal of Public ... Vitamin D found in blood. , Researchers found ... than 9 nanograms/milliliter (ng/mL) were twice as likely to ...
    (Date:8/31/2014)... 01, 2014 GoDaddy, IX Web ... provide VPS (Virtual Private Server) hosting, which is ... into many servers, each of which has the ... dedicated computer. Top10BestSEOHosting.com has recently compared many professional ... companies are the best VPS hosting suppliers in ...
    (Date:8/31/2014)... September 01, 2014 With years of hard ... of great secondhand construction machines. Recently, the company has updated ... cheap used cat 966 loaders. All these items are guaranteed ... rates right now. , It is true that all ... are carefully selected by machine specialists. The firm is making ...
    (Date:8/31/2014)... Twin to twin transfusion syndrome (TTTS) almost took the ... born, but an innovative fetal surgery at the SSM St. ... , Now, their parents David and Theresa Colp want to build ... St. Louis at the St. Louis Fetal Care Institute. They are ... Delmar Blvd, St Louis, MO 63130) on Friday, Sept. 10 from ...
    (Date:8/31/2014)... NutriGold announces that its whole-food ... and berries, has been approved by ConsumerLab ... purity and label claims. , Most commercially ... genetically modified and chemically produced corn glucose through ... the use of a genetically modified microbe species ...
    Breaking Medicine News(10 mins):Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:GoDaddy, IX Web Hosting and Bluehost Are Awarded As Hosting Experts by Top10BestSEOHosting.com 2Health News:Delta Updates Its Wheel Loader Assortment With A Lot Of Cheap Used Cat 966 Loaders 2Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 2Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 3Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 2Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 3
    ... Record GAAP diluted EPS increased 34.2 percent to $0.51 from $0.38 in ... second-quarter 2007 - Record diluted EPS increased 30.2 percent ... ... revenues increased 15.6 percent to nearly $12.8 billion, - Specialty revenues increased 32.6 percent ...
    ... LEXINGTON, Mass., July 24 Tepha, Inc., a ... of resorbable polymers, announced,today that it has appointed ... President and Chief Operating Officer. Mr. Hartnett joins ... during which he,progressed from field sales, to marketing ...
    ... 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the ... China-based,medical device company that develops, manufactures and ... focused ultrasound tumor,therapy systems, today announces that ... the first quarter ended June 30, 2008 ...
    ... July 24 STAAR Surgical,Company (Nasdaq: ... marketer of,minimally invasive ophthalmic products, today announced ... (CMS) has designated two of STAAR,s new,aspheric ... (NTIOLs). The,lenses are the Afinity Collamer(R) Aspheric ...
    ... Ground-breaking Technology Debuts in the Trance(TM) 8 Performance Running ... ... BOTHELL, Wash., July 24 Leading performance running,company Brooks Sports, Inc. ... to consumers in the new Trance(TM),8 premium support shoe. Brooks designed ...
    ... MS -- Today, "actual age" and,"physical age" are ... their,bodies, by following the easy dietary and exercise ... look younger without drastic,measures., (Photo: http://www.newscom.com/cgi-bin/prnh/20080724/NYFNSU01 ... author, and frequent guest on,Oprah Winfrey,s program has ...
    Cached Medicine News:Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 2Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 3Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 4Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 5Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 6Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 7Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 8Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 9Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 10Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 11Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 12Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 13Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 14Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 15Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 16Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 17Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 18Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 19Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 20Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 21Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 22Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 23Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 24Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 25Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 26Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 27Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 28Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 29Health News:Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer 2Health News:China Medical Technologies to Announce Financial Results for the First Quarter Ended June 30, 2008 on August 4, 2008 2Health News:STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification 2Health News:STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification 3Health News:STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification 4Health News:Brooks(R) Sports Launches BioMoGo Biodegradable Shoe 2Health News:Brooks(R) Sports Launches BioMoGo Biodegradable Shoe 3
    Optimal solution for normal acetabulum and younger patients....
    The Pe-Plus offers an additional clinical option for replacing the acetabulum....
    ... Metal material and modularity into ... a fusion of technology and versatility ... for initial and long-term stability, but ... shell and liner options to address ...
    Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
    Medicine Products: